Inhibition of PKC with PKI depresses force and stiffness in agonist-stimulated vascular smooth muscle cells, suggesting PKC activation mediates agonist-induced force enhancement.
Answers are grounded in this paper and cite their sources.
PKC mediates agonist force enhancement in vascular smooth muscle; leaves open therapeutic targeting in vivo.
To determine whether activation of protein kinase C (PKC) is involved in the mechanism of agonist-induced force enhancement, force and stiffness were measured in both Ca(2+)- and agonist-stimulated contractions of single isolated alpha-toxin-permeabilized smooth muscle cells. PKC function was inhibited with the pseudosubstrate inhibitor (residues 19-31) of PKC (PKI). For Ca2+ activation, PKI did not change (P > 0.05) steady-state force or stiffness. However, for agonist activation at pCa 7 (n = 13), PKI depressed force by 28.7 +/- 4.5% (P < 0.05), in-phase stiffness by 35.4 +/- 4.0% (P < 0.05), and quadrature stiffness by 25.6 +/- 4.4% (P < 0.05), and for agonist activation at pCa 4 (n = 7), PKI depressed force by 25.8 +/- 2.9% (P < 0.05), in-phase stiffness by 35.6 +/- 5.6% (P < 0.05), and quadrature stiffness by 20.3 +/- 4.1% (P < 0.05). These results suggest that the agonist-induced force enhancement in alpha-toxin-permeabilized smooth muscle is due to the activation of PKC.
No takes yet. Share an insight, caveat, or question.
Frank V. Brozovich (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: